Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

intravitreal

intravitreal is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 16
Pipeline programs 26
News articles 0
Drug details — intravitreal
Class
—
Route
—
Patents
16
Programs
26
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

intravitreal is an FDA-listed pharmaceutical active ingredient.

Key facts

INN intravitreal

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 2.0 mg intravitreal aflibercept Phase 3 · Regeneron UK · Diabetic Macular Edema
  2. ADX-2191 (intravitreal methotrexate 0.8%) Phase 3 · Aldeyra Therapeutics · Proliferative Vitreoretinopathy
  3. Intravitreal Aflibercept Injection (IAI) Phase 3 · Regeneron UK · Proliferative Diabetic Retinopathy
  4. Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) Phase 3 · Regeneron UK · Diabetic Macular Edema
  5. Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) Phase 3 · Regeneron UK · Branch Retinal Vein Occlusion
  6. Intravitreal aflibercept injection [IAI] Phase 3 · Regeneron UK · Nonproliferative Diabetic Retinopathy
  7. 0.59 mg fluocinolone acetonide intravitreal implant Phase 2 · Bausch + Lomb · Diabetic Macular Edema
  8. Brimo PS DDS® Phase 2 · Allergan Pharmaceuticals International · Patients Who Participated in an Intravitreal Brimo PS DDS® S

Related patents

Browse patents

  1. US 12331099

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11732024

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11084865

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11066458

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10464992

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10400025

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9914763

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9580489

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9340594

    VEGF antagonist formulations for intravitreal administration

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8802107

    VEGF antagonist formulations for intravitreal administration

    Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8481046

    VEGF antagonist formulations for intravitreal administration

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8420619

    Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein

    Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8242093

    Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein

    Expires Mon Aug 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8092803

    VEGF antagonist formulations for intravitreal administration

    Expires Mon Jan 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7807164

    Lyophilized VEGF antagonist formulations for intravitreal administration

    Expires Mon Sep 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7608261

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is intravitreal?

intravitreal is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.